首页> 外文期刊>Journal of Indian Society of Periodontology >Case report on low dose of Cilnidipine: A fourth-generation calcium channel blocker-induced gingival overgrowth
【24h】

Case report on low dose of Cilnidipine: A fourth-generation calcium channel blocker-induced gingival overgrowth

机译:低剂量西尼地平的病例报告:第四代钙通道阻滞剂诱导的牙龈过度生长

获取原文
       

摘要

Drug-induced gingival overgrowth is a frequently observed adverse effect of antihypertensive drug calcium channel blockers (CCBs). Gingival enlargements are more common with the dihydropyridine class of CCBs. The fourth-generation dihydropyridine CCB Cilnidipine was introduced in 1995 and is used as an antihypertensive agent for patients in the Indian subcontinent. This is the first report in literature to document an isolated case of generalized gingival overgrowth induced by the long-term use of low dose of cilnidipine in an elderly female patient who is under antihypertensive therapy. Gingival overgrowth is an adverse drug reaction of new-generation CCB Cilnidipine when administered even as low-dose antihypertensive therapy agent. Physicians and dentists should identify such late changes in susceptible individuals.
机译:药物引起的牙龈过度生长是抗高血压药钙通道阻滞剂(CCB)的常见不良反应。牙龈增大在CCB的二氢吡啶类中更为常见。第四代二氢吡啶CCB西尼地平于1995年推出,被用作印度次大陆患者的降压药。这是文献中首次报道了长期服用低剂量西尼地平导致一名正在接受降压治疗的老年女性引起的广泛性牙龈过度生长的孤立案例。牙龈过度生长是新一代CCB西尼地平的不良药物反应,即使作为小剂量降压治疗剂给药也是如此。医师和牙医应在易感人群中识别出此类晚期变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号